Eli Lilly & Co. (LLY) isn’t interested in buying parts of Abbott Laboratories (ABT) when it splits next year, Lilly’s chief executive officer said. “We don’t believe large-scale combinations like that will add value for Lilly,” John Lechleiter said in a telephone interview today. “We remain focused on our strategy, which includes smaller deals and alliances.” To contact the reporter on this story: Simeon Bennett in Geneva at sbennett9@bloomberg.net
